|
|
|
|
|
|
|
|
|
|
|
06.11.25 - 22:06
|
MindMed Reports Q3 2025 Financial Results and Business Updates (Business Wire)
|
|
|
-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)--
--Anticipated topline data readout from first Phase 3 study of MM120 ODT in MDD (Emerge) accelerated to mid-2026, aligning with the anticipated initiation of second Phase 3 study in MDD (Ascend)--
--MM120 Phase 2b GAD Study published in the Journal of the American Medical Association (JAMA)--
--Continued advancement of pipeline with planned Phase 2a study initiation of MM402 in Autism Spectrum Disorder (ASD) in 4Q 2025--
--Cash, cash equivalents and marketable securities totaled $209.1 million as of September 30, 2025; completed underwritten public offering of common stock with net proceeds of $242.8 million on October 31, 2025--
--Conference call scheduled today at 4:30 p.m. EST--
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical...
|
|
|
03.11.25 - 13:06
|
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters′ Option to Purchase Additional Shares (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of $12.25 per common share. All of the shares were offered by MindMed. The gross proceeds from this offering were approximately $259 million, before deducting underwriting discounts and commissions and offering expenses payable by MindMed.
MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purposes. MindMed may also use a portion of the net proceeds to invest in or acquire additional businesses ...
|
|
|
30.10.25 - 21:03
|
MindMed to Report Q3 2025 Financial Results on November 6, 2025 (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, November 6, 2025 to report financial results for the third quarter ended September 30, 2025, and discuss recent business updates.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in t...
|
|
|
|
|
30.10.25 - 03:15
|
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $225 million. In addition, MindMed has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,756,250 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by MindMed.
MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purpose...
|
|
|
29.10.25 - 21:06
|
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, MindMed intends to grant the underwriters an option for a period of 30 days to purchase additional common shares at the public offering price, less underwriting discounts and commissions. All of the common shares and pre-funded warrants are being offered by MindMed.
MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purposes. MindMed may also use a portion of the net proceeds to invest in or acquire additional businesses or compounds that it believes are compl...
|
|
|
14.10.25 - 22:03
|
MindMed Announces New Employee Inducement Grant (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Company (the "Option") with an effective grant date of October 14, 2025. The Option has an exercise price equal to the closing price of MindMed's common shares on the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to the employee's continued employment.
The Option was granted as a material inducement to the employee's employment and was approved by MindMed's Compensation Committee on October 7, 2025, in accordance with Rule ...
|
|
|
|
|
|
|
|
|
22.09.25 - 22:06
|
MindMed Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 182,800 common shares of the Company (the "Options") with effective grant dates of September 15, 2025 and September 22, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each...
|
|
|
08.09.25 - 22:06
|
MindMed Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--$MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 78,750 common shares of the Company (the "Options") with effective grant dates of August 25, 2025, September 2, 2025 and September 8, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a materia...
|
|
|
|
|
|
|
|
|
07.08.25 - 12:00
|
1 Reason to Buy MindMed (MNMD) (Fool)
|
|
|
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
